Ilean Paduaoctaviani
Camuy, PRNPI 1730492679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 545 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations.
Across 545 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- AstraZeneca$2K
- Amgen$1K
- Merck$1K
- AbbVie$947
- PBG Puerto Rico LLC$828
- plus $5K from 32 others
What the payments were for
- Food & beverage$13,25097%
- Education$3943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 108 | $2,247 |
| AstraZeneca | 79 | $1,798 |
| Amgen | 46 | $1,320 |
| Merck | 54 | $1,069 |
| AbbVie | 38 | $947 |
| PBG Puerto Rico LLC | 37 | $828 |
| Sanofi | 17 | $673 |
| Eli Lilly Export S.A. Puerto Rico Branch | 22 | $628 |
| Johnson & Johnson(2 entities) | 21 | $526 |
| Sobi, Inc | 12 | $495 |
| Genentech USA, Inc. | 22 | $487 |
| Lilly USA, LLC | 6 | $459 |
| Novartis | 13 | $281 |
| Seagen Inc. | 6 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $189 |
| Puma Biotechnology, Inc. | 7 | $156 |
| Regeneron Healthcare Solutions, Inc. | 6 | $137 |
| ADC Therapeutics America, Inc. | 1 | $120 |
| Bayer Puerto Rico Inc. | 5 | $120 |
| Pfizer | 2 | $104 |
| Bristol Myers Squibb | 2 | $100 |
| Astellas Pharma US Inc | 5 | $92 |
| Gilead | 4 | $84 |
| GSK | 4 | $80 |
| Beigene USA, Inc. | 4 | $76 |
| Incyte Corporation | 3 | $61 |
| Exelixis Inc. | 2 | $46 |
| Caris MPI, Inc. | 2 | $43 |
| Bayer | 2 | $42 |
| Eisai Inc. | 2 | $40 |
| Rigel Pharmaceuticals, Inc. | 2 | $38 |
| Tempus AI, Inc | 1 | $28 |
| Pharmaessentia USA Corporation | 1 | $25 |
| Clovis Oncology, Inc. | 1 | $20 |
| Organon | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SprycelDasatinib | 22 | $388,125 |
| PromactaEltrombopag Olamine | 14 | $119,734 |
| EliquisApixaban | 11 | $5,116 |
| Exemestane | 41 | $3,117 |
| Anastrozole | 188 | $2,790 |
| Letrozole | 56 | $668 |
| ValacyclovirValacyclovir Hcl | 12 | $247 |
| Hydroxyurea | 13 | $221 |
| Famotidine | 41 | $217 |
| Ondansetron Hcl | 17 | $214 |
| Gabapentin | 20 | $139 |
| Alendronate Sodium | 22 | $114 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $107 |
| Omeprazole | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel | $2,247 | $388,12522 claims |
| NovartisPromacta | $281 | $119,73414 claims |
| PfizerEliquis | $104 | $5,11611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.